Slide 1: Patrys New CEO Introduction and Presentation to Investors
ASX & Media Release Patrys New CEO Introduction and For personal use only Presentation to Investors Melbourne, Australia; 02 June 2011: Following the appointment of new CEO Dr Marie Roskrow, Patrys Limited (ASX: PAB) is today commencing a series of presentations to professional and institutional inv
Slide 2: Investor Presentation June 2011
For personal use only Investor Presentation June 2011 Dr. Marie Roskrow Chief Executive Officer ASX: PAB
Slide 3: Safe Harbour Statement
Safe Harbour Statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 4: Presentation Overview
Presentation Overview For personal use only 1. Company Overview and Key Investment Highlights 2. Technology and Pipeline Overview 3. Future Plans 3
Slide 5: Company Overview
Company Overview For personal use only Patrys is an ASX listed, Australian based international biotechnology company focused on the discovery and development of natural human antibody therapeutics for the treatment of cancer KEY STATISTICS – 31 MAY 2011 (A$) 1 YEAR SHARE PERFORMANCE ASX Code PAB $0.
Slide 6: Key Investment Highlights
Key Investment Highlights Multiple potential blockbuster drugs for cancer, currently in clinical or late preclinical For personal use only development. • PAT-SM6 − melanoma and multiple solid tumours Exciting Antibody • PAT-LM1 − multiple solid tumours Pipeline • PAT-SC1 − gastric and potentially
Slide 7: Leader in Natural Human Antibodies
Leader in Natural Human Antibodies For personal use only Natural Human Target Preclinical Antibody Clinical Trials Identification Development Technology Ability to develop 40,000 antibodies Technology platform Innovative trial antibodies and move captured & screened allows capture of design provides
Slide 8: Presentation Overview
Presentation Overview For personal use only 1. Company Overview and Key Investment Highlights 2. Technology and Pipeline Overview 3. Future Plans 7
Slide 9: Technology Overview
Technology Overview For personal use only Spleen / lymph nodes Proprietary antibody isolated from multiple capture technology patients 27% IgG 61% 12% IgA IgM 0.10% 40,000 MAbs Captured IgG 14 products 99.90% evaluated to IgM >300 MAbs Passed Screening date Tests approx. 99.9% are IgM’s 8 Non-Confid
Slide 10: Why IgM's?
Why IgM’s? For personal use only IgM’s are the body’s first line of defence as part of the innate immune system Have shown anti-tumour activity in both mice and humans and exhibit therapeutic promise Have an excellent safety profile in humans Specificity of IgM’s potential lead to reduced si
Slide 11: Pipeline Overview
Pipeline Overview For personal use only Product Discovery Preclinical Phase I Phase II Phase III PAT-SM6 – Melanoma PAT-SM6 – Solid Tumours PAT-LM1 – Solid Tumours PAT-SC1 – Gastric Cancer PAT-SC1 – Solid Tumours 4 Undisclosed Abs 7 Others Work conducted at Patrys GmbH, Germany 250 Backup Abs Partne
Slide 12: CSL Collaboration
CSL Collaboration For personal use only Agreement signed in January 2010 Covers 4 early stage antibodies Driven by CSL interest in disease targets & antibodies Multi-stage/milestone structure First milestone achieved and related payment made to Patrys Status update expected CY2011 11
Slide 13: PAT-SC1 (Gastric Cancer)
PAT-SC1 (Gastric Cancer) For personal use only First antibody from pipeline evaluated in PAT-SC1 clinic Origin PAT-SC1 Originally licensed to AstraZeneca returned Binding to CD55 to Patrys in 2009 Target: Binds to CD55 target on multiple types of CD55 Tumour Cell CD55 cancer cells Safe in 51
Slide 14: PAT-LM1
PAT-LM1 For personal use only Lung Cancer Animal Model Potent killing activity across multiple Overview cancers Binds to NONO protein expressed in >98% of over 200 different patient tumours screened Target: Third party research confirms NONO several critical roles of NONO in cancer Further t
Slide 15: PAT-SM6
PAT-SM6 For personal use only Potent killing activity across a range Overview of cancers GRP78 Binds to a protein GRP78 that is expressed in 98% of cancer tissues Target: screened GRP78 Substantial literature reports on role of GRP78 in cancer and promise for cancer-specific targeting/treatmen
Slide 16: PAT-SM6 Melanoma Trial and Beyond
PAT-SM6 Melanoma Trial and Beyond For personal use only PAT-SM6 Clinical Development Phase I/IIa Trial Current Trial Extension Trial (preliminary) Indication Melanoma Solid tumours No. Patients 9 (55% complete) +18 18+ Up to 9 mg/kg Dose Range 0.15 mg/kg 9 mg/kg multidose Primary Endpoint Safety Ant
Slide 17: Presentation Overview
Presentation Overview For personal use only 1. Company Overview and Key Investment Highlights 2. Technology and Pipeline Overview 3. Future Plans 16
Slide 18: Future Plans – Next 18 months
Future Plans – Next 6 -18 months For personal use only Current Point in Time June ‘11 Dec ‘11 Dec ‘12 PAT-SM6 PAT-SM6 • Complete current trial • Phase I/IIa multidose solid tumour trial • Commence extension trial • Phase I human imaging study commencement • Additional clinical centres • Multiple pre
Slide 19: For Further Information
For Further Information For personal use only Contact Details Dr. Marie Roskrow, Chief Executive Officer Roger McPherson, Chief Financial Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com 18